Wall Street analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings of ($0.61) per share for the current quarter, Zacks reports. Five analysts have made estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.79). Intellia Therapeutics reported earnings of ($0.52) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 17.3%. The firm is expected to report its next earnings results on Wednesday, August 7th.
On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.40) per share for the current financial year, with EPS estimates ranging from ($3.08) to ($1.90). For the next fiscal year, analysts forecast that the business will post earnings of ($2.86) per share, with EPS estimates ranging from ($3.75) to ($2.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 2nd. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $9.43 million. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. The firm’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share.
A number of equities research analysts have issued reports on NTLA shares. Wedbush restated an “outperform” rating on shares of Idera Pharmaceuticals in a research report on Friday, May 3rd. Roth Capital started coverage on Crispr Therapeutics in a research report on Monday, June 10th. They set a “buy” rating and a $50.00 price objective on the stock. Evercore ISI started coverage on Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective on the stock. BidaskClub upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, Robert W. Baird started coverage on Intellia Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $23.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $25.31.
Hedge funds and other institutional investors have recently modified their holdings of the company. Tortoise Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock worth $34,000 after buying an additional 1,000 shares during the period. Quantamental Technologies LLC raised its holdings in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock worth $56,000 after buying an additional 3,043 shares during the period. Resources Investment Advisors Inc. purchased a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $92,000. NumerixS Investment Technologies Inc purchased a new stake in shares of Intellia Therapeutics in the first quarter worth approximately $110,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Intellia Therapeutics by 942.0% in the first quarter. BNP Paribas Arbitrage SA now owns 7,648 shares of the company’s stock worth $131,000 after buying an additional 6,914 shares during the period. Hedge funds and other institutional investors own 74.34% of the company’s stock.
NTLA stock traded down $0.11 during midday trading on Tuesday, reaching $17.10. 397,369 shares of the company traded hands, compared to its average volume of 798,326. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $32.95. The company has a quick ratio of 7.74, a current ratio of 7.74 and a debt-to-equity ratio of 0.06. The stock’s 50 day simple moving average is $15.32. The firm has a market cap of $781.66 million, a price-to-earnings ratio of -8.64 and a beta of 2.62.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: Trading signals using Bollinger bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.